Avanos Medical, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Sigfrido Delgado, SVP, Operations of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Scott Michael Galovan, SVP, Chief Financial Officer of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
David Pacitti, Chief Executive Officer of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Julie Ann Shimer, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Patrick J Oleary, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Indrani Lall Franchini, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Lisa Egbuonu-Davis, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Gary Blackford, a Director of Avanos Medical, Inc., reported multiple transactions in common stock on July 27, 2026.
NYSE
Avanos Medical, Inc. reports that Director Gary Blackford was issued 12,003 restricted share units on May 8, 2026, replacing prior units.
NYSE
A Form 4 filing reveals that Avanos Medical Director Lisa Egbuonu-Davis was granted 12,003 restricted share units on May 8, 2026, replacing previous units.
NYSE
Indrani Lall Franchini, a Director at Avanos Medical, Inc., was granted 12,003 restricted share units on May 8, 2026, replacing previous units.
NYSE
Avanos Medical, Inc. reports that Director Patrick J. O'Leary was issued 12,003 restricted share units on May 8, 2026, replacing prior units.
NYSE
A Form 4 filing reveals that Julie Ann Shimer, a Director at Avanos Medical, Inc., was granted 12,003 restricted share units on May 8, 2026.
NYSE
Avanos Medical's CFO Scott Michael Galovan surrendered 4,228 shares to cover tax liabilities following the vesting of restricted stock units.
NYSE
Sigfrido Delgado, SVP of Operations at Avanos Medical, surrendered 4,264 shares to cover tax liabilities following the vesting of restricted stock units.
NYSE
Avanos Medical CEO David Pacitti surrendered 21,194 shares to satisfy tax obligations following the vesting of restricted stock units.
NYSE
AVANOS Medical's SVP of Operations, Sigfrido Delgado, filed an amended Form 4 to correct an error in a previously reported stock option grant.
NYSE
AVANOS MEDICAL's CFO, Scott Galovan, filed an amended Form 4 to correct an error in a previous filing regarding his stock option grant.
NYSE
AVANOS MEDICAL, INC. CEO David Pacitti filed an amended Form 4 to correct an error in previously reported stock option grants.
NYSE
Avanos Medical, Inc. filed an amended Form 4 to correct an error in the calculation of stock options granted to SVP of Operations, Sigfrido Delgado.
NYSE
AVANOS MEDICAL, INC. CEO David Pacitti filed an amended Form 4 to correct an error in the calculation of stock options and restricted share units awarded on March 13, 2026.
NYSE
An amended SEC filing clarifies the equity awards granted to Avanos Medical's CFO, Scott Michael Galovan, correcting an error in stock option calculations.
NYSE
AVANOS MEDICAL, INC.'s Principal Accounting Officer, John Joseph Hurley, received an award of 2,211 time-based restricted share units.
NYSE
AVANOS MEDICAL, INC.'s SVP and CFO, Scott Michael Galovan, received significant equity awards and stock options as part of the company's long-term incentive plan.
NYSE
AVANOS MEDICAL, INC. CEO David Pacitti received 101,341 restricted share units and 239,354 employee stock options as part of the company's long-term incentive plan.
NYSE
AVANOS MEDICAL, INC. SVP of Operations, Sigfrido Delgado, received awards of 15,886 restricted stock units and 37,520 stock options.
NYSE
AVANOS MEDICAL, INC. SVP and Chief Commercial Officer Kerr Holbrook sold 15,000 shares of common stock through pre-arranged trading plans.
NYSE
AVANOS Medical's Principal Accounting Officer, John Joseph Hurley, reported the disposition of 345 common shares to cover tax obligations from vested restricted stock units.
NYSE
Avanos Medical Director Gary Blackford increased his beneficial ownership of company common stock through two purchase transactions totaling 60,000 shares.
NYSE
Michael Greiner, a former interim CEO of Avanos Medical, disposed of shares to cover tax withholding obligations upon the vesting of restricted share units.